George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Wynd
I’ve inherited a Hofner Club 60 though it was used by a friend in clubs around Merseyside in the 60s. It’s been retrofitted with Seymour Duncan pickups. Any idea what its worth?
I thought it would be nice to establish some common ground so I offer the following:
1. Clinical trial results have confirmed that the platform works
2. Published data confirms that AVA6000 works as expected with varying levels of efficacy for patients with differing characteristics.
3. The tight targeting of AVA6000 allows for an excellent range of dosing regimes in terms of frequency, potency and duration of treatment.
4. If all goes well Avacta are funded thru to at least the start of P2.
Al has intimated that he wants to keep control of AVA6000 but would seek future funding by licensing agreements with other drugs in the pipeline in particular AVA3996.
I am not sure we have a consensus on the SP. I can only make money on this if the SP rises or I get a dividend. I think a dividend is years off. Some on here are happy that they are funding cancer treatment development so saving lives. If this was my only aim I would donate my money to a cancer charity. I don’t subscribe to the line that IIs or BP are as thick as mince. I think that they have just as much data on Avacta as we do, if not more. And they certainly have more resources. It’s just that there are better places to invest for a more certain return right now.
Anyway I’ll stop now because I’ve veered into the realms of conjecture.
I still feel that there is much more upside gain to this than downside risk. But I won’t be buying any more until the next fund raise. However I have come to terms with the fact that if AVA6000 doesn’t deliver excellent arm2 results I will wish I had sold at 50p
GLA
Ice
I’m not after a row but you could have said the same thing anytime over the last few weeks and what has happened? It’s gone down. If you mean that by mid year it will be up again then I agree😄
Ice ffs stop the unfounded ramping. There is no new information to support a rise at this point other than how low the SP is at the moment
Jeez the management is so good they can’t even get a simple RNS right🤣
Watching
. . . and your considered opinion is what exactly?
Bella
Why do you persist in abusing anyone who doesn’t follow your Pom Pom waving delusion?
It isn’t a lie, it’s a fact. They have increased their short to 0.6 %.
It’s about time that the Pom Pom girls on here opened there eyes to facts rather than just ignoring them and posting wishful thinking based on f*ck all.
Timster posted;
“1. AVA6000 exhibited rapid distribution, with a half-life of 45 minutes backing up my assertion that dilution in the bloodstream is too rapid.
Comedy gold 😂😂😂😂😂”
Tim all you have shown here is that you haven’t bothered to read the article that started this thread off.
Watching
What is inaccurate about the fact I have quoted?
Ice
Yes of course I understand that and I wouldn’t be surprised if they move to a weekly dosing regime to keep the levels of AVA6000 as high as possible in order for as much as possible to be in bloodstream around TME. And of course it’s the precision of AVA6000 that enables this and why we are all here invested.
CTSFO
Yes if the rapid reduction in free AVA6000 is mainly due to it being cleaved in the TME then that is brilliant, but as I say based on the overall results including biopsies and what has happened to clinical trial design, then IMHO, it isn’t, it’s being excreted too quickly. Perhaps our metabolism and kidney function is far better in this respect than mice?
Dilution in terms of parts per million of AVA6000 versus blood. As uncleaved AVA6000 is excreted (or whatever the correct term is) from the body, the amount in the blood decreases. That’s what I mean by dilution. Therefore less available in TME to be cleaved.
Lovable
You are quoting dox half life. That is meaningless in my argument (other than ensuring that any cleaved dox that escapes from the TME is excreted quickly before it can do much harm to other organs). I was referring to the AVA6000 half life stated in the original article.
Oxygen
Right on and that’s why Al won’t do any deal that means he would lose control of his baby. Primarily he is in this because it’s his life’s work.
Tim
Thank god you’re still here. I was beginning to worry about you 😄
For me this is the clearest analysis of trial results. An excellent article but my takeaways are:
1. AVA6000 exhibited rapid distribution, with a half-life of 45 minutes backing up my assertion that dilution in the bloodstream is too rapid.
2. Tumor biopsy data demonstrated a mean concentration of doxorubicin in the TME of 860 ng/gm (range 76-2310 ng/gm, n=9). Which leads me to believe that there needs to be a lot of work done on targeting patients and dosing regime.
3. In contrast, blood samples collected at the biopsy showed a circulating free doxorubicin concentration of 8.3 ng/ml (range 2.4-15.9), indicating a higher concentration of doxorubicin in the tumor relative to plasma. Obviously supporting the conclusion that the platform works.
So we await the results analysis of arm2 to find out whether I’m selling my house to upsize or downsize 🤣🤣🤣. That’s a joke BTW.
Bella
Agree with all your points but we will only know when arm2 results are analysed
I refer you to my posts after the December briefing in which I questioned rate of AVA6000 cleaving versus rate of cleaved fox being excreted. The AVA6000 half life in the bloodstream is very short. I said that I thought the variable results in patients was a strong reason to delay P1a to insert a 2 weekly trial in the expectation that this would improve results to the extent that BP or IIs would be convinced enough to invest.
The Pom Pom girls poo pood this suggestion but I still feel that this was the main reason for the change in strategy. I think and hope that arm2 will give us the results we need but it is far from being a slam dunk and that is why we are where we are.
Al is the king of the ambiguous communication especially if it allows him to big up the prospects of Avacta. You have only yourselves to blame if you chose to read Al’s words in the best possible light and then over invest.
Bdoggg
Confident based on what? Reading tea leaves?
Hje306
Most investors would think of it as a support level. If you think about what investors were doing when it last hit that level then it’s obvious why it is regarded as such.
TT23
And you think that this “group” is much better when one posts something that upsets the Pom Pom wavers narrative???😄